At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
bevacizumab +1 moredrug
Likely dose
bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
In Brief
A Phase 2 clinical trial evaluating bevacizumab and RAD001 for Kidney Cancer. Completed, enrolled 80 participants across 12 sites.
Detailed Summary
This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., Novartis
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMay 2006
Primary CompletionNov 2008
Study CompletionMar 2011
TodayJul 2026
First PostedMay 9, 2006
Enrollment StartMay 1, 2006
Primary CompletionNov 1, 2008
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.1 years ago
Interventions
bevacizumabdrug
Bevacizumab 10mg/kg, IV infusion, every 2 weeks
RAD001drug
RAD001 10 mg by mouth daily